{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '8.2.', 'Withdrawal from the Study', '34', '8.3.', 'Lost to Follow Up', '35', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', '36', '9.1.', 'Efficacy Assessments', '36', '9.1.1.', 'FEV1', '36', '9.1.1.1.', 'Clinic Spirometry', '36', '9.1.1.2.', 'Mobile Spirometry', '36', '9.1.2.', 'SGRQ-C', '36', '9.1.3.', 'CAT', '37', '9.1.4.', 'COPD Exacerbations', '37', '9.1.5.', 'Patient Global Rating of Severity and Global Rating of', 'Change in Disease Severity', '37', '9.2.', 'Adverse Events', '38', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '38', '9.2.2.', 'Method of Detecting AEs and SAEs', '38', '9.2.3.', 'Follow-up of AEs and SAEs', '38', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', '39', '9.2.5.', 'Cardiovascular and Death Events', '39', '9.2.6.', 'Disease-Related Events and/or Disease-Related', 'Outcomes Not Qualifying as SAEs', '39', '9.2.7.', 'Pregnancy', '40', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', '40', '9.2.8.1.', 'Time Period for Detecting Medical Device', 'Incidents', '40', '9.2.8.2.', 'Follow-up of Medical Device Incidents', '41', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents', 'to Sponsor', '41', '9.2.8.4.', 'Regulatory Reporting Requirements for', 'Medical Device Incidents', '41', '9.3.', 'Treatment of Overdose', '42', '9.4.', 'Safety Assessments', '42', '9.4.1.', 'Physical Examinations', '42', '9.4.2.', 'Vital Signs', '42', '9.4.3.', 'Electrocardiograms', '43', '9.4.4.', 'Clinical Safety Laboratory Assessments', '43', '9.4.5.', 'Pneumonia', '43', '9.5.', 'Pharmacokinetics', '44', '9.6.', 'Pharmacodynamics', '44', '9.7.', 'Genetics', '44', '9.8.', 'Biomarkers', '44', '9.9.', 'Health Economics OR Medical Resource Utilization and Health', 'Economics', '45', '10. STATISTICAL CONSIDERATIONS', '45', '10.1.', 'Sample Size Determination', '45', '10.2. Randomization', '48', '10.3.', 'Populations for Analyses', '48', '10.4.', 'Statistical Analyses', '48', '10.4.1.', 'Efficacy Analyses', '48', '10.4.2.', 'Safety Analyses', '51', '5']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.4.3.', 'Other Analyses', '51', '10.4.4.', 'Interim Analyses', '51', '11. REFERENCES', '52', '12. APPENDICES', '55', '12.1. Appendix 1: Abbreviations and Trademarks', '55', '12.2.', 'Appendix 2: Clinical Laboratory Tests', '59', '12.3.', 'Appendix 3: Study Governance Considerations', '61', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '65', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', '71', '12.6.', 'Appendix 6: Genetics', '75', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', '76', '12.8.', 'Appendix 8: Medical Device Incidents: Definition and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '79', '12.9. Appendix 9: Neutrophil Safety and Study Treatment Restart', '81', '12.10. Appendix 10: Country-specific requirements', '83', '12.11. Appendix 11 Protocol Amendment History', '84', '6']\n\n###\n\n", "completion": "END"}